MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
Kymera Therapeutics, Inc. (NASDAQ: KYMR)*
Organization & Developments: Kymera Therapeutics
Parents
Kymera Therapeutics, Inc. (NASDAQ: KYMR)*
Children
*A biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
2020: Kymera and Sanofi Enter Anti-Inflammatory Deal Worth More than $2 Billion
2021: Kymera: Targeting The Protein Degradation Space
2022: Kymera Therapeutics (KYMR) Investor Presentation - Slideshow_ seekingalpha.com
2022: Kymera: Upcoming Trial Data Will Make Or Break The Company_ seekingalpha.com
2023: Kymera Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Disease (NASDAQ:KYMR)
2023: Kymera: More Data Needed_ seekingalpha.com
2024: Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
2024: Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
2024: Kymera zeros in on immunology, seeks partners for cancer candidates
2024: Kymera: Protein Degradation Could Drive Dupixent-Like Value
2024: Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors_ seekingalpha.com
2025: Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line
2025: Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data
Jumps
Finance & Acquisitions: Kymera Therapeutics
Key People: Kymera Therapeutics